<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424838</url>
  </required_header>
  <id_info>
    <org_study_id>618366</org_study_id>
    <nct_id>NCT02424838</nct_id>
  </id_info>
  <brief_title>22 G - 25 G SINS Trial for Pancreatic Masses</brief_title>
  <acronym>SINS</acronym>
  <official_title>Randomized Trial Examining the Relationship Between Procedural Technique and Specimen Evaluation Methods in Patients Undergoing Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) of Pancreatic Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After patients have been screened and have signed informed consent, they will be taken to the
      endoscopy suite. Once the decision has been made to proceed with Fine Needle Aspiration
      (FNA), the subject will be randomized to 1 of 4 groups:

        -  22 gauge (G) needle with suction

        -  25 G needle with suction

        -  22 G needle without suction

        -  25 G needle without suction

      Follow-up Phone Call Phase:

      Unit staff will call patients 1 week after the procedure to check if patients had any adverse
      events from the procedure and this will be recorded onto the dataset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All adult patients referred to Florida Hospital for evaluation of a pancreatic mass lesion
      will be eligible for entry into the study. Patients will be approached at the time of
      procedural consent for the study.

        1. After written informed consent is taken, Endoscopic Ultrasound (EUS) will be performed
           under conscious sedation.

        2. At the time of EUS, patients who require FNA will be randomized to the two needles (22 G
           or 25 G needles) and to the two techniques (using suction or not using suction).

        3. Computer-generated randomization assignments using the block randomization method will
           be obtained from the statistician prior to study enrollment. These will be placed in
           sequentially numbered sealed opaque envelopes and opened by the endoscopy nurse
           immediately after the decision to perform FNA is made. The randomization sequence will
           specify the needle size to be used and whether or not suction will be applied for FNA.

        4. FNA will be performed in the standard fashion using one of the designated needle sizes
           (using the fanning technique to pass the needle 12-16 times into the lesion) by one of
           the experienced endosonographers in the unit. The needle stylet will be left in place
           for the first pass and then removed for subsequent passes. Suction will be applied
           during aspiration of the mass as dictated by the randomization sequence.

        5. First two passes will be performed to obtain tissue sample for cell block analysis.
           Therefore, the tissue obtained with the first and second passes will be expressed onto a
           slide and into test tubes for cell block analysis.

        6. From the third pass onwards, the aspirate obtained will be examined onsite by the
           cytopathologist, who will be available to interpret the slides immediately to determine
           diagnostic adequacy of the sample per standard practice. Once the diagnosis is made and
           the adequacy of the sample is affirmed by the cytopathologist, the procedure will be
           stopped and the echoendoscope will be withdrawn from the patient.

        7. Total number of passes to obtain a diagnostic cytological aspirate made will be recorded
           at the time of procedure, as well as the occurrence of needle dysfunction, technical
           failure, and any immediate complications.

        8. The samples taken will be transported to the pathology lab (per standard practice) where
           the cellular aspirate and cell block samples will be evaluated by the pathologist. 10%
           of samples from each subgroup (i.e. 22G with suction, 22G without suction, 25G with
           suction, 25G without suction) will be further analyzed for the presence of molecular
           markers for malignancy.

        9. After the appropriate observations are deemed satisfactory, patients will be discharged
           as per unit policy.

       10. Unit staff will call patients 1 week after the procedure to check if patients had any
           adverse events from the procedure and this will be recorded onto the dataset.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">April 3, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.</measure>
    <time_frame>7 days (cell block processing in lab)</time_frame>
    <description>The use of suction and a larger gauge needle during EUS-FNA is likely to increase the diagnostic yield of cell block. This may in turn translate to improved diagnosis and hence expedite patient management</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic adequacy of FNA cytology</measure>
    <time_frame>24 hours</time_frame>
    <description>1. Diagnostic adequacy of FNA cytology samples and comparison between the two needle sizes and the effect of application of suction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of passes to diagnosis</measure>
    <time_frame>24 hours</time_frame>
    <description>2. Median no. of passes required to obtain diagnostically adequate cytological samples, and comparison between the two needle sizes and suction vs. no suction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen bloodiness</measure>
    <time_frame>24 hours</time_frame>
    <description>3. Specimen bloodiness and comparison between the two needle sizes and two techniques (with and without suction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of needle dysfunction</measure>
    <time_frame>24 hours</time_frame>
    <description>4. Rate of needle dysfunction and technical failure, and comparison between the two needle sizes and two techniques (with and without suction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>3 days</time_frame>
    <description>5. Rate of complications following EUS-FNA, and comparison between the two needle sizes and two techniques (with and without suction)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>22 gauge with suction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 gauge without suction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 gauge with suction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 gauge without suction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-FNA of pancreatic masses</intervention_name>
    <description>EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.</description>
    <arm_group_label>22 gauge with suction</arm_group_label>
    <arm_group_label>22 gauge without suction</arm_group_label>
    <arm_group_label>25 gauge with suction</arm_group_label>
    <arm_group_label>25 gauge without suction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>22 gauge needle</intervention_name>
    <arm_group_label>22 gauge with suction</arm_group_label>
    <arm_group_label>22 gauge without suction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>25 gauge needle</intervention_name>
    <arm_group_label>25 gauge with suction</arm_group_label>
    <arm_group_label>25 gauge without suction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic
             mass lesions that require FNA

          2. Age â‰¥ 19 years

        Exclusion Criteria:

          1. Age &lt;19 years

          2. Unable to safely undergo EUS for any reason

          3. Coagulopathy (INR &gt;1.6, Thrombocytopenia with platelet count &lt;80,000/ml)

          4. Unable to provide consent for any reason

          5. Pregnancy (confirmed with Standard of Care urine pregnancy test for all women with
             child-bearing potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam S Varadarajulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share Individual Participant Data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

